Catalyst Wire Dossier Catalyst Wire Dossier

nivolumab/ipilimumab

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for nivolumab/ipilimumab, covering 2019-10-22 to 2023-02-06. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy [Phase 3]

See pricing